Literature DB >> 30848846

Vaginal axis after abdominal sacrocolpopexy versus vaginal sacrospinous fixation-a randomized trial.

Cassia Raquel Teatin Juliato1, Luiz Carlos Santos-Junior1, Edilson Benedito de Castro1, Sergio Sanjuan Dertkigil2, Luiz Gustavo Oliveira Brito1.   

Abstract

AIMS: To compare postoperative vaginal axis (VA) following vaginal sacrospinous fixation (VSF) or abdominal sacrocolpopexy (ASC) using magnetic resonance imaging (MRI) at postoperative period, in a randomized sample.
METHODS: Seventy-one patients randomized to VSF with an anterior mesh or ASC were recruited with a mean 27-month follow-up for pelvic MRI; 40 patients underwent the examination. VA was calculated in relation to the pelvic inclination correction line. All patients were submitted to physical examination according to the pelvic organ prolapse quantification system, subjective impression questionnaires and quality of life (QoL) questionnaires (International Consultation on Incontinence Questionnaire, ICIQ). Objective failure was defined as points Ba, Bp, or C > 0. Subjective cure was defined as questions 5a and 6a from the ICIQ-VS questionnaire equal to zero.
RESULTS: VA exhibited two portions (inferior and medium). Mean medium axis was equally more obtuse in VSF (85.9° ± 9.9°; P < 0.001) and ASC (87.1° ± 14.7°; P < 0.001) groups, with no difference between them. Mean inferior axis was more acute for both groups (VSF, 72.5° ± 19.1°, P < 0.001; ASC, 75.7° ± 15.5°, P < 0.001). All women had normal medium axes and 47.5% had inferior axis values above the 95th or below the fifth percentile, without differences regarding type of surgery performed. Women with abnormal vs normal VA did not present any difference regarding pre or postoperative physical examination, demographic characteristics, objective or subjective cure, patient satisfaction, QoL scores, or sexuality.
CONCLUSIONS: Both VSF and ASC deviate the physiological VA, both in its medium and inferior portions, where values fall outside normality percentiles. However, this alteration was not associated with worse objective, subjective, QoL, or sexual outcomes.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  magnetic resonance imaging; pelvic organ prolapse; sacrocolpopexy; sacrospinous fixation; vaginal axis

Mesh:

Year:  2019        PMID: 30848846     DOI: 10.1002/nau.23970

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  5 in total

1.  Defining mechanisms of recurrence following apical prolapse repair based on imaging criteria.

Authors:  Shaniel T Bowen; Pamela A Moalli; Steven D Abramowitch; Mark E Lockhart; Alison C Weidner; Cecile A Ferrando; Charles W Nager; Holly E Richter; Charles R Rardin; Yuko M Komesu; Heidi S Harvie; Donna Mazloomdoost; Amaanti Sridhar; Marie G Gantz
Journal:  Am J Obstet Gynecol       Date:  2021-06-01       Impact factor: 10.693

2.  The establishment of a 3D anatomical coordinate system for defining vaginal axis and spatial position.

Authors:  Deanna C E Sinex; Shaniel T Bowen; Ahmed Kashkoush; Arianna Rosemond; Danielle Carter; Prahlad G Menon; Pamela A Moalli; Steven D Abramowitch
Journal:  Comput Methods Programs Biomed       Date:  2021-05-16       Impact factor: 7.027

3.  The feasibility of uterine-vaginal axis MRI-based as evaluation of surgical efficacy in women with pelvic organ prolapse.

Authors:  Haifeng Wang; Jihong Shen; Song Li; Zhenhua Gao; Kunbin Ke; Peng Gu
Journal:  Ann Transl Med       Date:  2022-04

4.  Comparison of the Axes and Positions of the Uterus and Vagina Between Women With and Without Pelvic Floor Organ Prolapse.

Authors:  Song Li; Xuewei Wen; Zhenhua Gao; Kunbin Ke; Jing Yang; Haifeng Wang; Yin Mo; Yizhen Zeng; Yuan Li; Daoming Tian; Jihong Shen
Journal:  Front Surg       Date:  2022-02-10

5.  Position and orientation of vaginal pessaries in situ on magnetic resonance imaging.

Authors:  Christopher X Hong; Elana Meer; Max Cioban; David J Tischfield; Daisy B Hassani; Heidi S Harvie
Journal:  Int Urogynecol J       Date:  2021-06-16       Impact factor: 2.894

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.